GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Cyclically Adjusted Book per Share

Biomarin Pharmaceutical (MIL:1BMRN) Cyclically Adjusted Book per Share : €20.55 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted book value per share for the three months ended in Mar. 2024 was €24.597. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €20.55 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biomarin Pharmaceutical's average Cyclically Adjusted Book Growth Rate was 10.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 14.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 14.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biomarin Pharmaceutical was 28.40% per year. The lowest was 13.20% per year. And the median was 18.30% per year.

As of today (2024-05-24), Biomarin Pharmaceutical's current stock price is €70.52. Biomarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €20.55. Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is 3.43.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biomarin Pharmaceutical was 27.64. The lowest was 3.47. And the median was 8.98.


Biomarin Pharmaceutical Cyclically Adjusted Book per Share Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted Book per Share Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 20.55

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Biomarin Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomarin Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=24.597/131.7762*131.7762
=24.597

Current CPI (Mar. 2024) = 131.7762.

Biomarin Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201406 7.316 100.560 9.587
201409 7.939 100.428 10.417
201412 8.311 99.070 11.055
201503 13.982 99.621 18.495
201506 13.043 100.684 17.071
201509 12.670 100.392 16.631
201512 13.645 99.792 18.018
201603 12.676 100.470 16.626
201606 10.452 101.688 13.545
201609 13.730 101.861 17.762
201612 15.189 101.863 19.649
201703 14.940 102.862 19.140
201706 14.197 103.349 18.102
201709 13.451 104.136 17.021
201712 13.497 104.011 17.100
201803 12.887 105.290 16.129
201806 13.913 106.317 17.245
201809 14.042 106.507 17.374
201812 14.635 105.998 18.194
201903 14.516 107.251 17.835
201906 14.604 108.070 17.808
201909 15.543 108.329 18.907
201912 15.626 108.420 18.992
202003 16.221 108.902 19.628
202006 15.866 108.767 19.222
202009 18.964 109.815 22.757
202012 18.571 109.897 22.268
202103 19.139 111.754 22.568
202106 19.204 114.631 22.076
202109 19.754 115.734 22.492
202112 20.527 117.630 22.996
202203 21.564 121.301 23.426
202206 22.979 125.017 24.221
202209 24.831 125.227 26.130
202212 23.331 125.222 24.552
202303 23.196 127.348 24.003
202306 23.463 128.729 24.018
202309 24.362 129.860 24.722
202312 24.075 129.419 24.513
202403 24.597 131.776 24.597

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Biomarin Pharmaceutical  (MIL:1BMRN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=70.52/20.55
=3.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biomarin Pharmaceutical was 27.64. The lowest was 3.47. And the median was 8.98.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biomarin Pharmaceutical Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (MIL:1BMRN) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (MIL:1BMRN) Headlines

No Headlines